{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:18:08Z","timestamp":1769595488900,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100006129","name":"FCT","doi-asserted-by":"publisher","award":["SFRH\/SINTD\/96409\/2013"],"award-info":[{"award-number":["SFRH\/SINTD\/96409\/2013"]}],"id":[{"id":"10.13039\/100006129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1093\/ehjcvp\/pvx028","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T07:18:18Z","timestamp":1504595898000},"page":"111-118","source":"Crossref","is-referenced-by-count":35,"title":["Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis"],"prefix":"10.1093","volume":"4","author":[{"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal"}]},{"given":"Cl\u00e1udio","family":"David","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Cardiology Department, Centro Cardiovascular da Universidade de Lisboa (CCUL), Centro Acad\u00e9mico M\u00e9dico de Lisboa (CAML), Faculdade de Medicina, Universidade de Lisboa, Portugal"}]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Centro de Estudos de Medicina Baseada na Evid\u00eancia (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Portuguese Collaborating Centre of the Cochrane Iberoamerican Network, Faculdade de Medicina, Universidade de Lisboa, Portugal"}]},{"given":"Joaquim J","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal"}]},{"given":"Fausto J","family":"Pinto","sequence":"additional","affiliation":[{"name":"Cardiology Department, Centro Cardiovascular da Universidade de Lisboa (CCUL), Centro Acad\u00e9mico M\u00e9dico de Lisboa (CAML), Faculdade de Medicina, Universidade de Lisboa, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"key":"key\n\t\t\t\t20180315055247_pvx028-B1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","article-title":"Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis","volume":"100","author":"Caldeira","year":"2014","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00415-014-7462-0","article-title":"Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis","volume":"262","author":"Caldeira","year":"2015","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40256-015-0132-5","article-title":"Tolerability and acceptability of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: systematic review and meta-analysis","volume":"15","author":"Caldeira","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B4","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","article-title":"Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis","volume":"101","author":"Caldeira","year":"2015","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/ehjcvp\/pvv002","article-title":"New oral anticoagulants: a practical guide for physicians","volume":"1","author":"Hinojar","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ehjcvp\/pvw032","article-title":"Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA)","volume":"3","author":"Salmonson","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B9","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u2018valvular\u2019 atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B10","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/01.STR.31.11.2628","article-title":"Predictors of cerebrovascular events and death among patients with valvular heart disease: a population-based study","volume":"31","author":"Petty","year":"2000","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B12","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B13","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Bmj"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B14","author":"Lefebvre","year":"2011"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B15","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Vahanian","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B19","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B21","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B22","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1161\/STROKEAHA.112.673558","article-title":"Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Ntaios","year":"2012","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B25","volume-title":"Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0","author":"Sterne","year":"2011"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B27","doi-asserted-by":"crossref","first-page":"1179545x17704660","DOI":"10.1177\/1179545X17704660","article-title":"Thromboprophylaxis with apixaban in patients undergoing major orthopedic surgery: meta-analysis and trial-sequential analysis","volume":"10","author":"Caldeira","year":"2017","journal-title":"Clin Med Insights Blood Disord"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B28","doi-asserted-by":"crossref","first-page":"i1754","DOI":"10.1136\/bmj.i1754","article-title":"Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis","volume":"353","author":"Rodrigues","year":"2016","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B29","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with Warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of Dabigatran versus Warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus Warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA Pilot Study","volume":"16","author":"Dur\u00e3es","year":"2016","journal-title":"Drugs R D"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B33","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B34","first-page":"A17277","article-title":"Apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE","volume":"132(Suppl 3)","author":"Pokorney","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B35","doi-asserted-by":"crossref","first-page":"2194-2194","DOI":"10.1016\/S0735-1097(16)32195-7","article-title":"Outcomes in 2824 patients with valvular heart disease treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"67","author":"Renda","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B36","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.repc.2016.12.012","article-title":"The era of the novel oral anticoagulants in Portugal","volume":"36","author":"Caldeira","year":"2017","journal-title":"Rev Port Cardiol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40266-017-0476-4","article-title":"Prescription patterns of non-vitamin K oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012-2015: a study from the Norwegian Prescription Database","volume":"34","author":"Urbaniak","year":"2017","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B39","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/bcp.13299","article-title":"Trends in the prescription of novel oral anticoagulants in UK primary care","volume":"83","author":"Loo","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B40","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCOUTCOMES.113.000661","article-title":"Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation","volume":"6","author":"Canestaro","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11239-013-0989-6","article-title":"Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries","volume":"37","author":"Krejczy","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.repc.2015.07.004","article-title":"Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal","volume":"34","author":"Costa","year":"2015","journal-title":"Rev Port Cardiol"},{"key":"key\n\t\t\t\t20180315055247_pvx028-B43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/4\/2\/111\/24260541\/pvx028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:23:56Z","timestamp":1570062236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/4\/2\/111\/4104940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,6]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvx028","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2017,9,6]]}}}